Cardiovascular Disease Patients
Developing innovative therapy for
heart and cardiovascular disease
Vericel’s mission is to help cardiovascular disease patients realize the promise of a patient-specific, expanded multicellular therapy called ixmyelocel-T.By starting with the patient’s own bone marrow, which is accepted by the patient’s immune system, we believe we can eliminate both the risk of rejection and that of having to use immunosuppressive therapy pre- or post-therapy.
Clinical trials for heart disease treatment
Vericel is currently conducting clinical trials for two diseases: dilated cardiomyopahy (DCM) and critical limb ischemia (CLI).
Dilated Cardiomyopathy: Dilated cardiomyopathy (DCM) is the most common form of heart failure. We are administering a clinical trial for dilated cardiomyopathy, currently recruiting in Phase 2b. Learn more about DCM clinical trials.
Critical Limb Ischemia: Critical limb ischemia (CLI) is a severe type of peripheral arterial disease (PAD) caused by chronic inflammatory processes associated with atherosclerosis that result in markedly reduced blood flow to the legs, feet and hands. Vericel is conducting a clinical trial for critical limb ischemia in Phase 3. This trial is currently active and enrolling patients. Learn more about CLI clinical trials.
Contact us to learn more about Vericel, our stem cell therapy research and the progress of our clinical trials.
CLI in the news
See the affect our CLI clinical trial is having on one Montana patient, as reported by WDAF-TV, Fox 4, Kansas City.